This document describes a study using the ODIN text mining system to extract relationships between genes, drugs, and diseases from biomedical literature and validate those relationships against the PharmGKB knowledge base. The researchers developed methods to improve relationship ranking and conducted a revalidation experiment with curators from Stanford evaluating a sample of automatically extracted relationships. The curators provided feedback that led to improvements in the interactive curation interface to better suit their needs. Lessons were learned about obtaining user requirements and rapidly implementing and testing prototypes to develop usable curation tools.
Gampa Srinivas is seeking a position in formulation research and development with a leading pharmaceutical company. He has over 1.8 years of experience in R&D formulation at Leiutis Pharmaceuticals. His experience includes formulation development of injectables, depot formulations, lyophilized products, and more. He is proficient in quality by design, pharmacokinetics, and using software like WinNonlin. He holds an M.Pharm from NIPER Raebareli and a B.Pharm from Nalanda College of Pharmacy.
USING NLP APPROACH FOR ANALYZING CUSTOMER REVIEWScsandit
The Web considers one of the main sources of customer opinions and reviews which they are represented in two formats; structured data (numeric ratings) and unstructured data (textual comments). Millions of textual comments about goods and services are posted on the web by customers and every day thousands are added, make it a big challenge to read and understand them to make them a useful structured data for customers and decision makers. Sentiment
analysis or Opinion mining is a popular technique for summarizing and analyzing those opinions and reviews. In this paper, we use natural language processing techniques to generate some rules to help us understand customer opinions and reviews (textual comments) written in the Arabic language for the purpose of understanding each one of them and then convert them to a structured data. We use adjectives as a key point to highlight important information in the text then we work around them to tag attributes that describe the subject of the reviews, and we associate them with their values (adjectives).
BioDBCore: Current Status and Next DevelopmentsPascale Gaudet
The document discusses BioDBCore, a collaborative project aimed at gathering and standardizing metadata about biological databases. It provides an overview of BioDBCore's goals of improving data integration, encouraging standards, and maximizing resources. BioDBCore is led by Pascale Gaudet and Philippe Rocca-Serra and implemented on the BioSharing website. The document outlines the BioDBCore descriptors for databases and provides an example entry for the dictyBase database. It discusses maintaining and expanding BioDBCore records with the help of database providers and journals.
Aptamer Base: A collaborative knowledge base to describe aptamers and SELEX experiments, by Cruz-Toledo, Jose; McKeague, Maureen; Zhang, Xueru; Giamberardino, Amanda; McConnell, Erin; Francis, Tariq; DeRosa, Maria; Dumontier, Michel.
Presented at the 5th International Biocuration Conference, hosted by PIR in Washington, DC, April 2-4, 2012.
Directly e-mailing authors of newly published papers encourages community curation, by Stephanie Bunt, Gary Grumbling, Helen Field, Steven Marygold, Thom Kaufman, Kathy Matthews, Nick Brown and Gillian Millburn.
Presented at the 5th International Biocuration Conference, hosted by PIR in Washington, DC, April 2-4, 2012.
Using computational predictions to improve literature-based Gene Ontology ann...Pascale Gaudet
Using computational predictions to improve literature-based Gene Ontology annotations
The document discusses using computational gene ontology (GO) predictions to identify potential errors or areas for improvement in manually curated, literature-based GO annotations. Discrepancies between manual and computational annotations are analyzed to flag genes for review. Several attributes of flagged genes are examined to help prioritize curation efforts, including type of discrepancy, GO aspect, literature support, and source of computational prediction. While most current literature-based GO annotations are accurate, comparing to computational predictions provides an approach to continually improve annotation quality over time. Additional work is still needed to develop predictive models to better target genes most likely to need annotation updates.
Gampa Srinivas is seeking a position in formulation research and development with a leading pharmaceutical company. He has over 1.8 years of experience in R&D formulation at Leiutis Pharmaceuticals. His experience includes formulation development of injectables, depot formulations, lyophilized products, and more. He is proficient in quality by design, pharmacokinetics, and using software like WinNonlin. He holds an M.Pharm from NIPER Raebareli and a B.Pharm from Nalanda College of Pharmacy.
USING NLP APPROACH FOR ANALYZING CUSTOMER REVIEWScsandit
The Web considers one of the main sources of customer opinions and reviews which they are represented in two formats; structured data (numeric ratings) and unstructured data (textual comments). Millions of textual comments about goods and services are posted on the web by customers and every day thousands are added, make it a big challenge to read and understand them to make them a useful structured data for customers and decision makers. Sentiment
analysis or Opinion mining is a popular technique for summarizing and analyzing those opinions and reviews. In this paper, we use natural language processing techniques to generate some rules to help us understand customer opinions and reviews (textual comments) written in the Arabic language for the purpose of understanding each one of them and then convert them to a structured data. We use adjectives as a key point to highlight important information in the text then we work around them to tag attributes that describe the subject of the reviews, and we associate them with their values (adjectives).
BioDBCore: Current Status and Next DevelopmentsPascale Gaudet
The document discusses BioDBCore, a collaborative project aimed at gathering and standardizing metadata about biological databases. It provides an overview of BioDBCore's goals of improving data integration, encouraging standards, and maximizing resources. BioDBCore is led by Pascale Gaudet and Philippe Rocca-Serra and implemented on the BioSharing website. The document outlines the BioDBCore descriptors for databases and provides an example entry for the dictyBase database. It discusses maintaining and expanding BioDBCore records with the help of database providers and journals.
Aptamer Base: A collaborative knowledge base to describe aptamers and SELEX experiments, by Cruz-Toledo, Jose; McKeague, Maureen; Zhang, Xueru; Giamberardino, Amanda; McConnell, Erin; Francis, Tariq; DeRosa, Maria; Dumontier, Michel.
Presented at the 5th International Biocuration Conference, hosted by PIR in Washington, DC, April 2-4, 2012.
Directly e-mailing authors of newly published papers encourages community curation, by Stephanie Bunt, Gary Grumbling, Helen Field, Steven Marygold, Thom Kaufman, Kathy Matthews, Nick Brown and Gillian Millburn.
Presented at the 5th International Biocuration Conference, hosted by PIR in Washington, DC, April 2-4, 2012.
Using computational predictions to improve literature-based Gene Ontology ann...Pascale Gaudet
Using computational predictions to improve literature-based Gene Ontology annotations
The document discusses using computational gene ontology (GO) predictions to identify potential errors or areas for improvement in manually curated, literature-based GO annotations. Discrepancies between manual and computational annotations are analyzed to flag genes for review. Several attributes of flagged genes are examined to help prioritize curation efforts, including type of discrepancy, GO aspect, literature support, and source of computational prediction. While most current literature-based GO annotations are accurate, comparing to computational predictions provides an approach to continually improve annotation quality over time. Additional work is still needed to develop predictive models to better target genes most likely to need annotation updates.
The document summarizes recent developments in using machine learning techniques for computational drug docking. It finds that machine learning methods, such as random forests, can more accurately predict binding affinity between proteins and ligands compared to traditional scoring functions. Specifically, the best random forest model achieved a correlation of 0.803 between predicted and experimental binding affinity, compared to 0.644 for classical scoring functions. Machine learning also more accurately ranks ligands and identifies the top binding pose. The document concludes that machine learning is better able to utilize relevant molecular features for computational drug docking compared to traditional methods.
3 d virtual screening of pknb inhibitors using dataAbhik Seal
The document discusses protein kinase PknB, which is essential for cell division and metabolism in gram-positive bacteria. It then discusses methods for targeting protein kinases, including small molecule kinase inhibitors that target the ATP binding pocket. Finally, it discusses data fusion techniques for combining results from multiple search methods or data sources, including similarity fusion, group fusion, and reciprocal rank fusion.
In spite of extensive effort by industry and academia to develop new drugs, there are still several diseases that are in need of therapeutic agents and have yet to be developed.
10 years the identification rate of disease-associated targets has been higher than the therapeutics identification rate.
Nevertheless, it is apparent that computational tools provide high hopes that many of the diseases under investigation can be brought under control.
This document discusses molecular docking, which is a computational method used in structure-based drug design to predict the preferred orientation of molecules when bound to their protein targets to form stable complexes. It begins by introducing drug discovery and computational chemistry approaches. It then defines molecular docking and describes different docking types and software. Applications of docking in modern drug discovery are presented, along with case studies and achievements that have resulted in new drug classes. The document concludes that docking contributes promisingly to drug discovery by aiding in target identification and lead optimization.
RSC|ChemSpider is one of the world’s largest online resources for chemistry related data and services. Developed with the intention of delivering access to structure-based chemistry data via the internet the ChemSpider platform hosts over 26 million unique chemical compounds aggregated from over 400 data sources and provides an environment for the community to both annotate and curate these existing data as well as deposit new data to the system. The search system delivers flexible querying capabilities together with links to external sites for publication and patent data. This presentation will review the present capabilities of the ChemSpider system providing direct examples of how to use the system to source high quality data of value to chemists. We will discuss some of the challenges associated with validating data quality and examine how ChemSpider is a part of the new “semantic web for chemistry”. ChemSpider has also spawned a number of additional projects include ChemSpider SyntheticPages for hosting openly peer-reviewed chemical synthesis articles, Learn Chemistry Wiki for students learning chemistry and SpectraSchool for learning spectroscopy.
Various Computational Tools used in Drug DesignFirujAhmed2
Drug discovery is the process of identifying and developing new medications or drugs to treat diseases and improve human health. It involves a multidisciplinary approach that combines scientific research, experimentation, and testing to discover and create effective and safe pharmaceutical compounds.
Drug design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient.
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS santosh Kumbhar
Molecular docking is a computational method used in structure-based drug design to predict how biological macromolecules interact with other molecules. It attempts to predict the preferred orientation of one molecule to another when bound to each other to form a stable complex. Docking is useful for predicting the binding orientation of small molecule drug candidates to their protein targets in order to predict their interaction and to design effective inhibitors. There are various types of docking software available that implement different algorithms to predict the binding orientation and affinity between molecules rapidly and accurately to help identify potential lead compounds for drug development. Molecular docking has contributed to the discovery of several new drug classes and is playing an increasingly important role in modern computer-aided drug design and virtual
Chandrakant Roy has over 10 years of experience in clinical research as a research associate, clinical trial assistant, and clinical research coordinator. He has worked on Phase III and Phase IV clinical trials across various therapeutic areas. Mr. Roy holds an M.Sc. in Biomedical Sciences and a post-graduate diploma in clinical research. He is proficient in ICH GCP guidelines and has experience in clinical data management, monitoring, and pharmacovigilance activities. Currently, he works as a research associate at Quest Care Pvt Ltd conducting BA/BE studies.
The document discusses issues with data quality in public domain databases used for drug repurposing, noting errors that proliferate between databases as data is shared and sourced. It advocates for collaboration on data curation efforts, adopting standards for data representation and licensing, and developing apps and semantic web approaches to facilitate crowdsourcing data analysis and feedback. The goal is to improve data quality to enable more accurate computational modeling for drug discovery.
Omics int conference series analbioanal dr sudeb mandal jr scientist vimta ...Dr. Sudeb Mandal
This document summarizes presentations from the ANALBIOANAL 2010 conference track on regulatory bioanalysis and challenges. It lists the session chairs, titles of six presentations, and brief biographies of two presenters. The presentations covered analytical strategies for doping analysis, challenges in regulated bioanalysis with case studies, preformulation challenges for bioavailability/bioequivalence studies, the Global Harmonization Task Force, and method validation for determining meptyldinocap residues in grapes using LC-MS/MS.
This systematic review and meta-analysis analyzed the current literature comparing the clinical performance of direct composite resin restorations versus indirect restorations for restoring endodontically treated posterior teeth. Databases were screened and randomized clinical trials and prospective/retrospective studies comparing direct and indirect restorations were included. A meta-analysis found that for the short term (2.5-3 years), there was low-quality evidence of no difference in tooth survival or restoration quality between direct and indirect restorations. High-quality clinical trials controlling for factors like amount of coronal tooth tissue are still needed.
Molecular docking is a method for predicting how two molecules, such as a ligand and its protein target, will interact and fit together in three dimensions. Docking has become an important tool in drug discovery for identifying potential binding conformations between drug candidates and protein targets. The key steps in a typical docking workflow involve selecting the receptor and ligand molecules, then using software to computationally predict the orientation of binding and evaluate the fit through scoring functions. Popular molecular docking software packages include AutoDock, GOLD, and Glide. Applications of docking include virtual screening in drug discovery and lead optimization.
New Drug Design & Discovery discusses the process of drug discovery and design. It begins with an introduction to how drugs work in the human body to modulate functions. The drug discovery process is then described as a long, expensive endeavor involving chemical synthesis, clinical development, and formulation. Computer-aided drug design uses molecular modeling and structure-based approaches to predict ligand-receptor binding and identify biological targets in silico. Combinatorial chemistry and high-throughput screening allow for the rapid synthesis and testing of large libraries of compounds. The goal is to develop more potent and safer drugs through these computational and high-throughput methods.
This document discusses docking scoring functions, which are mathematical functions used to predict the binding affinity between molecules after docking. There are three main applications of scoring functions: determining the binding mode of a ligand on a protein, predicting absolute binding affinity, and identifying potential drug hits through virtual screening. The document outlines different classes of scoring functions, including force field-based, empirical, knowledge-based, consensus, and shape/chemical complementary scores. It provides examples of popular docking programs that utilize different scoring function approaches.
Where is drug discovery going? Christopher A. Lipinski outlines several key points about changes in drug discovery approaches. He notes that the traditional target-based approach has limitations and that phenotypic screening, drug repurposing, and multi-targeted discovery may be more promising avenues. Lipinski also discusses challenges with academic target identification and the need for greater industry-academic collaboration to bridge the "translational valley of death".
COMPUTER AIDED DRUG DESIGN BYJayant_Nimkar78JAYANTNIMKAR
This document discusses computer aided drug design (CADD). It begins with a brief history of drug design from the 19th century to modern computational methods. It then covers the introduction, context, benefits and limitations of CADD. The main benefits are cost savings compared to traditional experimentation and the ability to screen large libraries of compounds more quickly. Limitations include lack of quality data and challenges with modeling complex targets. The document outlines the main stages of the CADD process and concludes that while computational, it still requires experimental validation and has helped reduce drug development costs.
COMPUTER AISES DRUG DESIGN .BY JAYA NT NIMKAR78JAYANTNIMKAR
This document discusses computer aided drug design (CADD). It begins with a brief history of drug design from the 19th century to modern computational methods. It then covers the introduction, context, benefits and limitations of CADD. The main benefits are cost savings compared to traditional experimentation and the ability to screen large libraries of compounds more quickly. Limitations include lack of quality data and challenges with modeling complex targets. The document outlines the main stages of the CADD process and concludes that while computational, it still requires experimental validation and has helped reduce drug development costs.
Webinar: New RMC - Your lead_optimization Solution June082017Ann-Marie Roche
The document discusses Reaxys Medicinal Chemistry and how it supports hit-to-lead and lead optimization processes. It provides high quality data on topics like efficacy, ADMET properties, and animal models to help computational and medicinal chemists. The pX concept normalizes bioactivity measurements like IC50, Ki, and % inhibition into a single comparable metric, making it possible to compare compound affinity regardless of the metric reported. This allows researchers to more easily search for and analyze active compounds.
The document summarizes recent developments in using machine learning techniques for computational drug docking. It finds that machine learning methods, such as random forests, can more accurately predict binding affinity between proteins and ligands compared to traditional scoring functions. Specifically, the best random forest model achieved a correlation of 0.803 between predicted and experimental binding affinity, compared to 0.644 for classical scoring functions. Machine learning also more accurately ranks ligands and identifies the top binding pose. The document concludes that machine learning is better able to utilize relevant molecular features for computational drug docking compared to traditional methods.
3 d virtual screening of pknb inhibitors using dataAbhik Seal
The document discusses protein kinase PknB, which is essential for cell division and metabolism in gram-positive bacteria. It then discusses methods for targeting protein kinases, including small molecule kinase inhibitors that target the ATP binding pocket. Finally, it discusses data fusion techniques for combining results from multiple search methods or data sources, including similarity fusion, group fusion, and reciprocal rank fusion.
In spite of extensive effort by industry and academia to develop new drugs, there are still several diseases that are in need of therapeutic agents and have yet to be developed.
10 years the identification rate of disease-associated targets has been higher than the therapeutics identification rate.
Nevertheless, it is apparent that computational tools provide high hopes that many of the diseases under investigation can be brought under control.
This document discusses molecular docking, which is a computational method used in structure-based drug design to predict the preferred orientation of molecules when bound to their protein targets to form stable complexes. It begins by introducing drug discovery and computational chemistry approaches. It then defines molecular docking and describes different docking types and software. Applications of docking in modern drug discovery are presented, along with case studies and achievements that have resulted in new drug classes. The document concludes that docking contributes promisingly to drug discovery by aiding in target identification and lead optimization.
RSC|ChemSpider is one of the world’s largest online resources for chemistry related data and services. Developed with the intention of delivering access to structure-based chemistry data via the internet the ChemSpider platform hosts over 26 million unique chemical compounds aggregated from over 400 data sources and provides an environment for the community to both annotate and curate these existing data as well as deposit new data to the system. The search system delivers flexible querying capabilities together with links to external sites for publication and patent data. This presentation will review the present capabilities of the ChemSpider system providing direct examples of how to use the system to source high quality data of value to chemists. We will discuss some of the challenges associated with validating data quality and examine how ChemSpider is a part of the new “semantic web for chemistry”. ChemSpider has also spawned a number of additional projects include ChemSpider SyntheticPages for hosting openly peer-reviewed chemical synthesis articles, Learn Chemistry Wiki for students learning chemistry and SpectraSchool for learning spectroscopy.
Various Computational Tools used in Drug DesignFirujAhmed2
Drug discovery is the process of identifying and developing new medications or drugs to treat diseases and improve human health. It involves a multidisciplinary approach that combines scientific research, experimentation, and testing to discover and create effective and safe pharmaceutical compounds.
Drug design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient.
MOLECULAR DOCKING AND RELATED DRUG DESIGN ACHIEVEMENTS santosh Kumbhar
Molecular docking is a computational method used in structure-based drug design to predict how biological macromolecules interact with other molecules. It attempts to predict the preferred orientation of one molecule to another when bound to each other to form a stable complex. Docking is useful for predicting the binding orientation of small molecule drug candidates to their protein targets in order to predict their interaction and to design effective inhibitors. There are various types of docking software available that implement different algorithms to predict the binding orientation and affinity between molecules rapidly and accurately to help identify potential lead compounds for drug development. Molecular docking has contributed to the discovery of several new drug classes and is playing an increasingly important role in modern computer-aided drug design and virtual
Chandrakant Roy has over 10 years of experience in clinical research as a research associate, clinical trial assistant, and clinical research coordinator. He has worked on Phase III and Phase IV clinical trials across various therapeutic areas. Mr. Roy holds an M.Sc. in Biomedical Sciences and a post-graduate diploma in clinical research. He is proficient in ICH GCP guidelines and has experience in clinical data management, monitoring, and pharmacovigilance activities. Currently, he works as a research associate at Quest Care Pvt Ltd conducting BA/BE studies.
The document discusses issues with data quality in public domain databases used for drug repurposing, noting errors that proliferate between databases as data is shared and sourced. It advocates for collaboration on data curation efforts, adopting standards for data representation and licensing, and developing apps and semantic web approaches to facilitate crowdsourcing data analysis and feedback. The goal is to improve data quality to enable more accurate computational modeling for drug discovery.
Omics int conference series analbioanal dr sudeb mandal jr scientist vimta ...Dr. Sudeb Mandal
This document summarizes presentations from the ANALBIOANAL 2010 conference track on regulatory bioanalysis and challenges. It lists the session chairs, titles of six presentations, and brief biographies of two presenters. The presentations covered analytical strategies for doping analysis, challenges in regulated bioanalysis with case studies, preformulation challenges for bioavailability/bioequivalence studies, the Global Harmonization Task Force, and method validation for determining meptyldinocap residues in grapes using LC-MS/MS.
This systematic review and meta-analysis analyzed the current literature comparing the clinical performance of direct composite resin restorations versus indirect restorations for restoring endodontically treated posterior teeth. Databases were screened and randomized clinical trials and prospective/retrospective studies comparing direct and indirect restorations were included. A meta-analysis found that for the short term (2.5-3 years), there was low-quality evidence of no difference in tooth survival or restoration quality between direct and indirect restorations. High-quality clinical trials controlling for factors like amount of coronal tooth tissue are still needed.
Molecular docking is a method for predicting how two molecules, such as a ligand and its protein target, will interact and fit together in three dimensions. Docking has become an important tool in drug discovery for identifying potential binding conformations between drug candidates and protein targets. The key steps in a typical docking workflow involve selecting the receptor and ligand molecules, then using software to computationally predict the orientation of binding and evaluate the fit through scoring functions. Popular molecular docking software packages include AutoDock, GOLD, and Glide. Applications of docking include virtual screening in drug discovery and lead optimization.
New Drug Design & Discovery discusses the process of drug discovery and design. It begins with an introduction to how drugs work in the human body to modulate functions. The drug discovery process is then described as a long, expensive endeavor involving chemical synthesis, clinical development, and formulation. Computer-aided drug design uses molecular modeling and structure-based approaches to predict ligand-receptor binding and identify biological targets in silico. Combinatorial chemistry and high-throughput screening allow for the rapid synthesis and testing of large libraries of compounds. The goal is to develop more potent and safer drugs through these computational and high-throughput methods.
This document discusses docking scoring functions, which are mathematical functions used to predict the binding affinity between molecules after docking. There are three main applications of scoring functions: determining the binding mode of a ligand on a protein, predicting absolute binding affinity, and identifying potential drug hits through virtual screening. The document outlines different classes of scoring functions, including force field-based, empirical, knowledge-based, consensus, and shape/chemical complementary scores. It provides examples of popular docking programs that utilize different scoring function approaches.
Where is drug discovery going? Christopher A. Lipinski outlines several key points about changes in drug discovery approaches. He notes that the traditional target-based approach has limitations and that phenotypic screening, drug repurposing, and multi-targeted discovery may be more promising avenues. Lipinski also discusses challenges with academic target identification and the need for greater industry-academic collaboration to bridge the "translational valley of death".
COMPUTER AIDED DRUG DESIGN BYJayant_Nimkar78JAYANTNIMKAR
This document discusses computer aided drug design (CADD). It begins with a brief history of drug design from the 19th century to modern computational methods. It then covers the introduction, context, benefits and limitations of CADD. The main benefits are cost savings compared to traditional experimentation and the ability to screen large libraries of compounds more quickly. Limitations include lack of quality data and challenges with modeling complex targets. The document outlines the main stages of the CADD process and concludes that while computational, it still requires experimental validation and has helped reduce drug development costs.
COMPUTER AISES DRUG DESIGN .BY JAYA NT NIMKAR78JAYANTNIMKAR
This document discusses computer aided drug design (CADD). It begins with a brief history of drug design from the 19th century to modern computational methods. It then covers the introduction, context, benefits and limitations of CADD. The main benefits are cost savings compared to traditional experimentation and the ability to screen large libraries of compounds more quickly. Limitations include lack of quality data and challenges with modeling complex targets. The document outlines the main stages of the CADD process and concludes that while computational, it still requires experimental validation and has helped reduce drug development costs.
Webinar: New RMC - Your lead_optimization Solution June082017Ann-Marie Roche
The document discusses Reaxys Medicinal Chemistry and how it supports hit-to-lead and lead optimization processes. It provides high quality data on topics like efficacy, ADMET properties, and animal models to help computational and medicinal chemists. The pX concept normalizes bioactivity measurements like IC50, Ki, and % inhibition into a single comparable metric, making it possible to compare compound affinity regardless of the metric reported. This allows researchers to more easily search for and analyze active compounds.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...AyushGadhvi1
learning occurs when a stimulus (unconditioned stimulus) eliciting a response (unconditioned response) • is paired with another stimulus (conditioned stimulus)
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfrightmanforbloodline
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
1. Using ODIN for a PharmGKB revalidation experiment
Fabio Rinaldi1 , Simon Clematide1 , Yael Garten2 , Michelle
Whirl-Carrillo2 , Li Gong2 , Joan M. Hebert2 , Katrin Sangkuhl2 , Caroline
F. Thorn2 , Teri E. Klein2 , Russ B. Altman2 .
1 OntoGene group, University of Zurich
2 PharmGKB group, Stanford University
Biocuration 2012
2. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
Introduction
PharmGKB
OntoGene
IE Approach
Entities
Interactions
Revalidation
Results
Conclusion
Outlook
Acknowledgments
Extra
ME Ranking
Evaluation
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 2 / 42
3. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
PharmGKB
Mission
PharmGKB is a pharmacogenomics knowledge resource that encompasses
clinical information, potentially clinically actionable gene-drug associations
and genotype-phenotype relationships
Approach
PharmGKB collects, curates and disseminates knowledge about the impact
of human genetic variation on drug responses through the many activities,
including Annotating genetic variants and gene-drug-disease relationships
via literature reviews
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 3 / 42
4. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
PharmGKB
Mission
PharmGKB is a pharmacogenomics knowledge resource that encompasses
clinical information, potentially clinically actionable gene-drug associations
and genotype-phenotype relationships
Approach
PharmGKB collects, curates and disseminates knowledge about the impact
of human genetic variation on drug responses through the many activities,
including Annotating genetic variants and gene-drug-disease relationships
via literature reviews
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 3 / 42
5. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
http://www.pharmgkb.org/
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 4 / 42
6. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
OntoGene group
Aims
Develop innovative text mining technologies for the automatic extraction
of information from the biomedical literature.
http://www.ontogene.org/
Selected results
PPI,IMT BioCreative 2006
PPI BioCreative 2009 (best results)
ACT, IMT, IAT, BioCreative 2010
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 5 / 42
7. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
OntoGene group
Aims
Develop innovative text mining technologies for the automatic extraction
of information from the biomedical literature.
http://www.ontogene.org/
Selected results
PPI,IMT BioCreative 2006
PPI BioCreative 2009 (best results)
ACT, IMT, IAT, BioCreative 2010
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 5 / 42
8. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
SASEBio: Missions
SASEBio: Semi-automated semantic enrichment of biomedical texts
Mission I “Relation/Text Mining”: Extraction of semantic relations
between biomedical entities (proteins, genes, drugs) using linguistic
text mining methods
Mission II “Literature Curation”: Development of a flexible interactive
curation interface for efficient human validation and annotation
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 6 / 42
9. Intro IE Approach Revalidation Results Conclusion Extra PharmGKB OntoGene
SASEBio: Missions
SASEBio: Semi-automated semantic enrichment of biomedical texts
Mission I “Relation/Text Mining”: Extraction of semantic relations
between biomedical entities (proteins, genes, drugs) using linguistic
text mining methods
Mission II “Literature Curation”: Development of a flexible interactive
curation interface for efficient human validation and annotation
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 6 / 42
15. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Introduction
PharmGKB
OntoGene
IE Approach
Entities
Interactions
Revalidation
Results
Conclusion
Outlook
Acknowledgments
Extra
ME Ranking
Evaluation
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 12 / 42
16. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Relations between Genes, Drugs, Diseases
PharmGKB: Pharmacogenomics Knowledge Base as a Gold Standard
Subset of information in PharmGKB used:
26,122 binary relations between diseases, drugs, and genes
5062 PubMed abstracts referenced
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 13 / 42
17. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Relations between Genes, Drugs, Diseases
PharmGKB: Pharmacogenomics Knowledge Base as a Gold Standard
Subset of information in PharmGKB used:
26,122 binary relations between diseases, drugs, and genes
5062 PubMed abstracts referenced
Goal
Compute high-quality relation candidates and rank them according to a
confidence score.
Information used for text mining
PubMed abstracts plus MeSH terms and chemical substances terms.
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 13 / 42
18. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Baseline: Abstract-wide Co-occurence-based Candidate
Relation Generation
Basic idea
Combine all concepts identified in the abstract into relation candidate
pairs.
However, do not combine concepts stemming from the same ambiguous
term.
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 14 / 42
19. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Baseline: Abstract-wide Co-occurence-based Candidate
Relation Generation
Basic idea
Combine all concepts identified in the abstract into relation candidate
pairs.
However, do not combine concepts stemming from the same ambiguous
term.
Basic ranking: Occurrences and zoning
Score of a pair of concepts c1 , c2 in an abstract (C = all concepts):
freq(c1 ) + freq(c2 )
score(c1 , c2 ) =
freq(C )
Text zone boosting: An occurrence in an article title is counted 10 times.
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 14 / 42
20. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Improving Relation Ranking
Core ideas for improved ranking
Identify noisy concepts recognized by term recognizer and penalize
them.
Weight individual concepts according to their likeliness to appear in a
gold relation!
Adapt ranking of relations to gold standard.
Combine the weights of individual concepts for the score of relation
candidates.
Generally penalize relations of the same type (rare phenomenon)
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 15 / 42
21. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Improving Relation Ranking
Core ideas for improved ranking
Identify noisy concepts recognized by term recognizer and penalize
them.
Weight individual concepts according to their likeliness to appear in a
gold relation!
Adapt ranking of relations to gold standard.
Combine the weights of individual concepts for the score of relation
candidates.
Generally penalize relations of the same type (rare phenomenon)
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 15 / 42
22. Intro IE Approach Revalidation Results Conclusion Extra Entities Interactions
Improving Relation Ranking
Core ideas for improved ranking
Identify noisy concepts recognized by term recognizer and penalize
them.
Weight individual concepts according to their likeliness to appear in a
gold relation!
Adapt ranking of relations to gold standard.
Combine the weights of individual concepts for the score of relation
candidates.
Generally penalize relations of the same type (rare phenomenon)
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 15 / 42
23. Intro IE Approach Revalidation Results Conclusion Extra
Introduction
PharmGKB
OntoGene
IE Approach
Entities
Interactions
Revalidation
Results
Conclusion
Outlook
Acknowledgments
Extra
ME Ranking
Evaluation
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 16 / 42
24. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Experiment
Goal
Revalidation of PharmGKB relations with respect to false positives.
Collaboration with Stanford Center for Biomedical Informatics
Research
Relations Articles
In 3059 out of 5378 articles we find all 2 8
relations. 3 9
4 2
Keep 1407 where number of relations > 1 and 5 3
≤ 20. 6-7 1
Almost half of 3059 contain only 1 relation. 8-9 1
10-20 1
Each of the 5 curators revalidates 25 articles
Sampling of articles according to number
relations per article
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 17 / 42
25. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Experiment
Goal
Revalidation of PharmGKB relations with respect to false positives.
Collaboration with Stanford Center for Biomedical Informatics
Research
Relations Articles
In 3059 out of 5378 articles we find all 2 8
relations. 3 9
4 2
Keep 1407 where number of relations > 1 and 5 3
≤ 20. 6-7 1
Almost half of 3059 contain only 1 relation. 8-9 1
10-20 1
Each of the 5 curators revalidates 25 articles
Sampling of articles according to number
relations per article
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 17 / 42
26. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Experiment
Goal
Revalidation of PharmGKB relations with respect to false positives.
Collaboration with Stanford Center for Biomedical Informatics
Research
Relations Articles
In 3059 out of 5378 articles we find all 2 8
relations. 3 9
4 2
Keep 1407 where number of relations > 1 and 5 3
≤ 20. 6-7 1
Almost half of 3059 contain only 1 relation. 8-9 1
10-20 1
Each of the 5 curators revalidates 25 articles
Sampling of articles according to number
relations per article
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 17 / 42
27. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Experiment
Goal
Revalidation of PharmGKB relations with respect to false positives.
Collaboration with Stanford Center for Biomedical Informatics
Research
Relations Articles
In 3059 out of 5378 articles we find all 2 8
relations. 3 9
4 2
Keep 1407 where number of relations > 1 and 5 3
≤ 20. 6-7 1
Almost half of 3059 contain only 1 relation. 8-9 1
10-20 1
Each of the 5 curators revalidates 25 articles
Sampling of articles according to number
relations per article
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 17 / 42
28. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Process and Categories
Revalidation process
Our initial setup from IAT BioCreative task: Curator deletes
unwanted relations and exports the wanted.
But curators didn’t like that: The want checkboxes for revalidation
categories for each relation
http://kitt.cl.uzh.ch/kitt/bcms/pharmgkbmeB/#pmid=11990384
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 18 / 42
29. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Process and Categories
Revalidation process
Our initial setup from IAT BioCreative task: Curator deletes
unwanted relations and exports the wanted.
But curators didn’t like that: The want checkboxes for revalidation
categories for each relation
Revalidation categories
Our initial setup: verified = true positive; falsified = false positive
But curators wanted more:
Need full text: A relation can only be revalidated by recourse to full
text
Negative relation: Article denies a relation between two entities
http://kitt.cl.uzh.ch/kitt/bcms/pharmgkbmeB/#pmid=11990384
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 18 / 42
30. Intro IE Approach Revalidation Results Conclusion Extra
Customized ODIN interface
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 19 / 42
31. Intro IE Approach Revalidation Results Conclusion Extra
Lessons Learnt for Usability
1 Ask experienced users what they want (or what they are used to)
2 Rapidly implement prototypes and get feedback from users!
(The use of a JavaScript framework allows this easily!)
3 Let the users test on real data!
4 Respect user needs (as far as possible or sensible)!
Goto item 1!
Prepare simple and good documentation!
Be prepared for the unforeseeable!
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 20 / 42
32. Intro IE Approach Revalidation Results Conclusion Extra
Lessons Learnt for Usability
1 Ask experienced users what they want (or what they are used to)
2 Rapidly implement prototypes and get feedback from users!
(The use of a JavaScript framework allows this easily!)
3 Let the users test on real data!
4 Respect user needs (as far as possible or sensible)!
Goto item 1!
Prepare simple and good documentation!
Be prepared for the unforeseeable!
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 20 / 42
33. Intro IE Approach Revalidation Results Conclusion Extra
Lessons Learnt for Usability
1 Ask experienced users what they want (or what they are used to)
2 Rapidly implement prototypes and get feedback from users!
(The use of a JavaScript framework allows this easily!)
3 Let the users test on real data!
4 Respect user needs (as far as possible or sensible)!
Goto item 1!
Prepare simple and good documentation!
Be prepared for the unforeseeable!
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 20 / 42
34. Intro IE Approach Revalidation Results Conclusion Extra
Lessons Learnt for Usability
1 Ask experienced users what they want (or what they are used to)
2 Rapidly implement prototypes and get feedback from users!
(The use of a JavaScript framework allows this easily!)
3 Let the users test on real data!
4 Respect user needs (as far as possible or sensible)!
Goto item 1!
Prepare simple and good documentation!
Be prepared for the unforeseeable!
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 20 / 42
35. Intro IE Approach Revalidation Results Conclusion Extra
Lessons Learnt for Usability
1 Ask experienced users what they want (or what they are used to)
2 Rapidly implement prototypes and get feedback from users!
(The use of a JavaScript framework allows this easily!)
3 Let the users test on real data!
4 Respect user needs (as far as possible or sensible)!
Goto item 1!
Prepare simple and good documentation!
Be prepared for the unforeseeable!
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 20 / 42
36. Intro IE Approach Revalidation Results Conclusion Extra
Lessons Learnt for Usability
1 Ask experienced users what they want (or what they are used to)
2 Rapidly implement prototypes and get feedback from users!
(The use of a JavaScript framework allows this easily!)
3 Let the users test on real data!
4 Respect user needs (as far as possible or sensible)!
Goto item 1!
Prepare simple and good documentation!
Be prepared for the unforeseeable!
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 20 / 42
37. Intro IE Approach Revalidation Results Conclusion Extra
Introduction
PharmGKB
OntoGene
IE Approach
Entities
Interactions
Revalidation
Results
Conclusion
Outlook
Acknowledgments
Extra
ME Ranking
Evaluation
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 21 / 42
38. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Results
reject
needs full text
negative
confirm
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 22 / 42
39. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Results by Relation Types
reject
needs full text
negative
confirm
150
Number of relations
100
50
0
Disease/Drug Disease/Ds. Drug/Drug Drug/Gene Gene/Gene
Relation types
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 23 / 42
40. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Results by Curators
reject
70 needs full text
negative
confirm
60
50
Number of relations
40
30
20
10
0
A B C D E
Curator
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 24 / 42
41. Intro IE Approach Revalidation Results Conclusion Extra
Revalidation Results by Confidence Score Ranking
1.0
confirm
negative
Relative distribution of decisions for curated relations
needs full text
reject
0.8
0.6
0.4
0.2
0.0
1. 2. 3−5. 6−20.
Rank of a relation according to the confidence score
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 25 / 42
42. Intro IE Approach Revalidation Results Conclusion Extra
Concept Identification Quality as Rated by Curators
bad
N/A
ok
good
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 26 / 42
43. Intro IE Approach Revalidation Results Conclusion Extra
Concept Identification Quality as Rated by Curators
25
N/A
good
ok
bad
20
15
Articles
10
5
0
A B C D E
Curator
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 27 / 42
44. Intro IE Approach Revalidation Results Conclusion Extra
Meantime for Decision Taking for One Relation
q
350
q
q
q
Meantime of curation time per article in seconds
300
q
250
q
200
q
150
q
q
100
q
q
q
50
q
q
0
A B C D E
Curator
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 28 / 42
45. Intro IE Approach Revalidation Results Conclusion Extra
Concept Identification Quality and Meantime for Decision
Taking
350 q
q
q q
Meantime of curation time per article in seconds
300
q
250
q
200
q
q
150
q
100
50
0
bad ok good
Rating of quality of concept identification per article
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 29 / 42
46. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
Introduction
PharmGKB
OntoGene
IE Approach
Entities
Interactions
Revalidation
Results
Conclusion
Outlook
Acknowledgments
Extra
ME Ranking
Evaluation
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 30 / 42
47. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
Conclusion
The PharmGKB resource is an interesting gold standard for relation
detection between drugs, genes and diseases (apart from the common
protein-protein interaction detection task)
Proper ranking is crucial for real-world applications.
Supervised machine learning methods improve rankings dramatically.
Usability of the interface as a crucial acceptability criteria.
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 31 / 42
48. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
Future Work
For measuring inter-annotator agreement, each article sample should
be revalidated by at least two curators
Another experiment for the detection of false negatives: Select
PubMed articles where our text mining systems suggests a
non-existing relation with high confidence score.
Consider other databases: we are interested in research collaborations.
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 32 / 42
49. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
Future Work
For measuring inter-annotator agreement, each article sample should
be revalidated by at least two curators
Another experiment for the detection of false negatives: Select
PubMed articles where our text mining systems suggests a
non-existing relation with high confidence score.
Consider other databases: we are interested in research collaborations.
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 32 / 42
50. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
Future Work
For measuring inter-annotator agreement, each article sample should
be revalidated by at least two curators
Another experiment for the detection of false negatives: Select
PubMed articles where our text mining systems suggests a
non-existing relation with high confidence score.
Consider other databases: we are interested in research collaborations.
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 32 / 42
51. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
SMBM 2012
Semantic Mining in Biomedicine, Zurich, September 3-4, 2012
http://www.smbm.eu/
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 33 / 42
52. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
SMBM 2012
Semantic Mining in Biomedicine, Zurich, September 3-4, 2012
http://www.smbm.eu/
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 33 / 42
53. Intro IE Approach Revalidation Results Conclusion Extra Outlook Acknowledgments
Acknowledgements
Yael Garten, Michelle Whirl-Carillo, Li Gong, Joan M. Hebert, Katrin
Sangkuhl, Caroline F. Thorn, Teri E. Klein, Russ B. Altman from
Stanford University
Gerold Schneider and Kaarel Kaljurand
Martin Romacker from NITAS, Novartis
Thank you for your attention!
Questions?
Biocuration 2012 Rinaldi et al. ODIN-PharmGKB 34 / 42